UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/650/0.1/18.06.25 | Market Closed - BOERSE MUENCHEN 03:40:12 2024-05-28 pm EDT | ||
| 0.96 EUR | -15.79% |
|
| Current month | +159.46% | ||
| 1 month | +100.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 0.96 | -15.79% |
| 24-05-27 | 1.14 | +0.88% |
| 24-05-24 | 1.13 | +10.78% |
| 24-05-23 | 1.02 | +6.25% |
| 24-05-22 | 0.96 | +7.87% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 03:40 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1R1A |
| ISIN | DE000HD1R1A1 |
| Date issued | 2024-01-08 |
| Strike | 650 $ |
| Maturity | 2025-06-18 (386 Days) |
| Parity | 10 : 1 |
| Emission price | 1.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.93 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.03 € |
| Spread % | 3.16% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Warrants
- Warrant
